Wall Street analysts expect that C.R. Bard, Inc. (NYSE:BCR) will announce earnings per share (EPS) of $2.84 for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for C.R. Bard’s earnings, with estimates ranging from $2.80 to $2.92. C.R. Bard reported earnings of $2.56 per share during the same quarter last year, which indicates a positive year over year growth rate of 10.9%. The business is scheduled to issue its next quarterly earnings results on Tuesday, July 25th.
According to Zacks, analysts expect that C.R. Bard will report full year earnings of $11.79 per share for the current year, with EPS estimates ranging from $11.63 to $11.91. For the next year, analysts anticipate that the firm will post earnings of $12.93 per share, with EPS estimates ranging from $12.49 to $13.15. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow C.R. Bard.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Sunday, April 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, beating the Zacks’ consensus estimate of $2.65 by $0.22. C.R. Bard had a return on equity of 48.72% and a net margin of 15.70%. The business had revenue of $938.80 million for the quarter, compared to analysts’ expectations of $916.15 million. During the same period last year, the firm earned $2.34 earnings per share. The business’s quarterly revenue was up 7.5% on a year-over-year basis.
BCR has been the topic of a number of research reports. Jefferies Group LLC reaffirmed a “hold” rating and issued a $237.00 price target on shares of C.R. Bard in a research note on Monday, March 27th. Zacks Investment Research lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Tuesday, March 28th. BMO Capital Markets reaffirmed a “buy” rating and issued a $255.00 price target on shares of C.R. Bard in a research note on Tuesday, April 11th. Cowen and Company raised their price target on shares of C.R. Bard from $240.00 to $317.00 and gave the company a “market perform” rating in a research note on Monday, April 24th. Finally, Morgan Stanley lowered shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. Ten research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. C.R. Bard has a consensus rating of “Hold” and a consensus price target of $271.31.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/08/09/2-84-earnings-per-share-expected-for-c-r-bard-inc-nysebcr-this-quarter-updated-updated-updated.html.
In other C.R. Bard news, VP Frank Lupisella, Jr. sold 3,622 shares of the stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $304.00, for a total value of $1,101,088.00. Following the completion of the sale, the vice president now owns 10,139 shares in the company, valued at approximately $3,082,256. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.80% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Parallel Advisors LLC increased its stake in C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock worth $153,000 after buying an additional 369 shares during the last quarter. Cribstone Capital Management LLC acquired a new stake in C.R. Bard during the first quarter worth approximately $130,000. Contravisory Investment Management Inc. increased its stake in C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock worth $136,000 after buying an additional 426 shares during the last quarter. Whittier Trust Co. increased its stake in C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock worth $147,000 after buying an additional 42 shares during the last quarter. Finally, ClariVest Asset Management LLC purchased a new stake in shares of C.R. Bard during the first quarter worth about $148,000. Institutional investors own 87.79% of the company’s stock.
Shares of C.R. Bard (BCR) traded up 0.46% during midday trading on Monday, hitting $320.04. The stock had a trading volume of 218,134 shares. The stock has a market cap of $23.18 billion, a PE ratio of 40.73 and a beta of 0.59. C.R. Bard has a 52-week low of $203.63 and a 52-week high of $320.06. The firm has a 50 day moving average price of $311.80 and a 200-day moving average price of $264.06.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 4th. Shareholders of record on Monday, July 24th will be issued a $0.26 dividend. The ex-dividend date of this dividend is Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a yield of 0.32%. C.R. Bard’s payout ratio is 13.21%.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.